Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy

The Journal of Experimental Medicine
Yasuhito HamaguchiThomas F Tedder

Abstract

CD20 monoclonal antibody (mAb) immunotherapy is effective for lymphoma and autoimmune disease. In a mouse model of immunotherapy using mouse anti-mouse CD20 mAbs, the innate monocyte network depletes B cells through immunoglobulin (Ig)G Fc receptor (FcgammaR)-dependent pathways with a hierarchy of IgG2a/c>IgG1/IgG2b>IgG3. To understand the molecular basis for these CD20 mAb subclass differences, B cell depletion was assessed in mice deficient or blocked for stimulatory FcgammaRI, FcgammaRIII, FcgammaRIV, or FcR common gamma chain, or inhibitory FcgammaRIIB. IgG1 CD20 mAbs induced B cell depletion through preferential, if not exclusive, interactions with low-affinity FcgammaRIII. IgG2b CD20 mAbs interacted preferentially with intermediate affinity FcgammaRIV. The potency of IgG2a/c CD20 mAbs resulted from FcgammaRIV interactions, with potential contributions from high-affinity FcgammaRI. Regardless, FcgammaRIV could mediate IgG2a/b/c CD20 mAb-induced depletion in the absence of FcgammaRI and FcgammaRIII. In contrast, inhibitory FcgammaRIIB deficiency significantly increased CD20 mAb-induced B cell depletion by enhancing monocyte function. Although FcgammaR-dependent pathways regulated B cell depletion from lymphoid tissues, both...Continue Reading

References

Jan 1, 1987·The Journal of Experimental Medicine·J P CoutelierJ Van Snick
Aug 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·D Herlyn, H Koprowski
Aug 12, 1993·The New England Journal of Medicine·M S KaminskiG M Butchko
Oct 23, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D G MaloneyR Levy
Aug 10, 1999·Drugs·S V OnrustJ A Balfour
Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Nov 28, 2001·Hematology·O W PressJ Timmerman
Aug 3, 2002·Nature Reviews. Immunology·Toshiyuki Takai
Oct 22, 2002·Immunogenetics·Ludmila V MechetinaAlexander V Taranin
Oct 31, 2002·Immunologic Research·Robert P KimberlyJeffrey C Edberg
Dec 21, 2002·Immunological Reviews·Randall S DavisMax D Cooper
Mar 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Carlos P TabordaArturo Casadevall
Jun 10, 2003·Arthritis and Rheumatism·Gregg J Silverman, Stuart Weisman
Sep 17, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wen-Kai Weng, Ronald Levy
Dec 23, 2003·International Immunology·Junji UchidaThomas F Tedder
Mar 3, 2005·Journal of Clinical Immunology·Toshiyuki Takai
Mar 22, 2005·The Journal of Immunology : Official Journal of the American Association of Immunologists·Yasuhito HamaguchiThomas F Tedder
Jul 26, 2005·Immunity·Falk NimmerjahnJeffrey V Ravetch
Dec 3, 2005·Science·Falk Nimmerjahn, Jeffrey V Ravetch

❮ Previous
Next ❯

Citations

Apr 2, 2013·Cancer Immunology, Immunotherapy : CII·Ann L WhiteMartin J Glennie
Feb 25, 2010·Annals of Hematology·Markus BiburgerFalk Nimmerjahn
Nov 23, 2006·Springer Seminars in Immunopathology·Falk Nimmerjahn
Dec 3, 2010·Immunologic Research·David J DiLilloThomas F Tedder
Jun 8, 2013·Cell Death and Differentiation·D HannaniL Zitvogel
Jul 4, 2006·Nature Reviews. Drug Discovery·Jeffrey L Browning
Mar 31, 2012·Nature Reviews. Drug Discovery·P Mark Hogarth, Geoffrey A Pietersz
Dec 8, 2007·Nature Reviews. Immunology·Falk Nimmerjahn, Jeffrey V Ravetch
Feb 16, 2013·Nature Reviews. Immunology·Inessa Schwab, Falk Nimmerjahn
Sep 26, 2008·Proceedings of the National Academy of Sciences of the United States of America·Heike AlbertFalk Nimmerjahn
Oct 27, 2010·Proceedings of the National Academy of Sciences of the United States of America·Falk NimmerjahnJeffrey V Ravetch
Mar 26, 2008·The Journal of Experimental Medicine·Rebecca J BrownlieKenneth G C Smith
Nov 24, 2011·Rheumatology·Nia Emami-Shahri, Thorsten Hagemann
Mar 29, 2008·Annual Review of Immunology·Falk Nimmerjahn, Jeffrey V Ravetch
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Emilian RacilaGeorge J Weiner
Dec 7, 2007·The Journal of Clinical Investigation·Chang-yun HuLi Wen
Sep 20, 2008·The Journal of Clinical Investigation·Takashi MatsushitaThomas F Tedder
Oct 25, 2011·The Journal of Clinical Investigation·Mayuka HorikawaThomas F Tedder
Feb 18, 2012·Blood·Freda K Stevenson, George T Stevenson
May 4, 2013·Immunotherapy·Takuro NoguchiHiroyoshi Nishikawa
Aug 7, 2013·EMBO Molecular Medicine·Peter BorossJeanette H W Leusen
Dec 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jean-David BouazizThomas F Tedder
May 9, 2007·Proceedings of the National Academy of Sciences of the United States of America·Falk NimmerjahnJeffrey V Ravetch
Jun 24, 2014·Trends in Immunology·Andrew J S FurnessSergio A Quezada
Mar 15, 2011·Expert Opinion on Biological Therapy·Sam MayesTim M Illidge
Jun 18, 2015·Expert Opinion on Drug Discovery·Piotr Smolewski, Tadeusz Robak
Feb 27, 2016·Signal Transduction and Targeted Therapy·Sasha BogdanovichJayakrishna Ambati
Apr 4, 2015·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Meng-Kun TsaiHong-Shiee Lai
Oct 24, 2015·Blood·Thomas R W TiptonStephen A Beers
Jul 1, 2008·Current Opinion in Immunology·Ronald P Taylor, Margaret A Lindorfer
Feb 13, 2007·Current Opinion in Immunology·Falk Nimmerjahn, Jeffrey V Ravetch
Aug 29, 2006·The American Journal of Pathology·Minoru HasegawaThomas F Tedder
Oct 6, 2015·The Journal of Clinical Investigation·Isaak QuastJan D Lünemann

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
dissection
FACS

Related Concepts

Related Feeds

Autoimmune Diseases

Autoimmune diseases occur as a result of an attack by the immune system on the body’s own tissues resulting in damage and dysfunction. There are different types of autoimmune diseases, in which there is a complex and unknown interaction between genetics and the environment. Discover the latest research on autoimmune diseases here.